Moody Aldrich Partners LLC raised its position in shares of Merus N.V. (NASDAQ:MRUS - Free Report) by 273.4% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 108,281 shares of the biotechnology company's stock after acquiring an additional 79,286 shares during the period. Moody Aldrich Partners LLC owned approximately 0.16% of Merus worth $4,558,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other hedge funds and other institutional investors also recently bought and sold shares of the stock. Net Worth Advisory Group bought a new position in shares of Merus during the 1st quarter worth $213,000. Avanza Fonder AB bought a new position in shares of Merus during the 1st quarter worth $118,000. Harbor Capital Advisors Inc. grew its position in shares of Merus by 49.0% during the 1st quarter. Harbor Capital Advisors Inc. now owns 64,374 shares of the biotechnology company's stock worth $2,710,000 after buying an additional 21,166 shares in the last quarter. GAMMA Investing LLC grew its position in shares of Merus by 2,153.6% during the 1st quarter. GAMMA Investing LLC now owns 631 shares of the biotechnology company's stock worth $27,000 after buying an additional 603 shares in the last quarter. Finally, California State Teachers Retirement System grew its position in shares of Merus by 7.5% during the 4th quarter. California State Teachers Retirement System now owns 41,149 shares of the biotechnology company's stock worth $1,730,000 after buying an additional 2,872 shares in the last quarter. Hedge funds and other institutional investors own 96.14% of the company's stock.
Insider Activity
In other news, COO Peter B. Silverman sold 34,000 shares of Merus stock in a transaction that occurred on Friday, June 20th. The stock was sold at an average price of $52.76, for a total value of $1,793,840.00. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. 4.57% of the stock is owned by corporate insiders.
Merus Price Performance
MRUS stock traded up $0.51 during trading on Friday, hitting $53.84. 222,443 shares of the company traded hands, compared to its average volume of 739,450. Merus N.V. has a 1 year low of $33.19 and a 1 year high of $62.98. The stock's 50-day simple moving average is $49.89 and its 200 day simple moving average is $45.24. The company has a market cap of $3.73 billion, a PE ratio of -13.20 and a beta of 1.00.
Merus (NASDAQ:MRUS - Get Free Report) last issued its quarterly earnings results on Wednesday, May 14th. The biotechnology company reported ($1.40) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.17) by ($0.23). The firm had revenue of $26.49 million during the quarter, compared to analyst estimates of $7.82 million. Merus had a negative return on equity of 35.99% and a negative net margin of 506.73%. Research analysts expect that Merus N.V. will post -3.85 earnings per share for the current year.
Wall Street Analysts Forecast Growth
A number of equities analysts have recently issued reports on the company. BMO Capital Markets set a $110.00 price target on Merus and gave the stock an "outperform" rating in a research report on Friday, May 23rd. Guggenheim reiterated a "buy" rating and issued a $109.00 price target on shares of Merus in a research note on Friday, March 28th. Needham & Company LLC reiterated a "buy" rating and issued a $75.00 price target on shares of Merus in a research note on Monday, May 19th. William Blair reiterated an "outperform" rating on shares of Merus in a research note on Monday, April 28th. Finally, Wells Fargo & Company decreased their price target on Merus from $91.00 to $89.00 and set an "overweight" rating for the company in a research note on Thursday, May 8th. Twelve analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, the company has an average rating of "Buy" and a consensus target price of $84.64.
Get Our Latest Stock Report on Merus
About Merus
(
Free Report)
Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1.
Recommended Stories
Before you consider Merus, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Merus wasn't on the list.
While Merus currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.
Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
